Teva Pharmaceutical Industries (TEVA) Shares Gap Down to $9.70

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) gapped down before the market opened on Thursday . The stock had previously closed at $9.99, but opened at $9.70. Teva Pharmaceutical Industries shares last traded at $8.84, with a volume of 42208030 shares traded.

A number of equities research analysts have recently weighed in on TEVA shares. ValuEngine downgraded shares of Teva Pharmaceutical Industries from a “sell” rating to a “strong sell” rating in a research report on Monday, March 25th. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a research report on Wednesday, March 20th. SunTrust Banks started coverage on shares of Teva Pharmaceutical Industries in a research report on Tuesday, March 19th. They issued a “hold” rating and a $17.00 price target for the company. Maxim Group reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, February 14th. Finally, Credit Suisse Group dropped their price target on shares of Teva Pharmaceutical Industries from $26.00 to $20.00 and set a “neutral” rating for the company in a research report on Thursday, February 14th. Four research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $19.21.

The stock has a market cap of $9.68 billion, a P/E ratio of 3.16, a P/E/G ratio of 1.20 and a beta of 1.30. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.62 and a current ratio of 0.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The business had revenue of $4.30 billion during the quarter, compared to the consensus estimate of $4.38 billion. During the same period in the previous year, the business earned $0.94 earnings per share. The company’s revenue was down 15.2% on a year-over-year basis. Equities research analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.26 EPS for the current fiscal year.

In other Teva Pharmaceutical Industries news, VP Notaristefani Carlo De sold 16,070 shares of the business’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $11.42, for a total transaction of $183,519.40. Following the sale, the vice president now owns 49,659 shares of the company’s stock, valued at $567,105.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Deborah A. Griffin sold 4,107 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $16.88, for a total transaction of $69,326.16. Following the sale, the insider now directly owns 2,941 shares in the company, valued at approximately $49,644.08. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,349 shares of company stock valued at $384,241. Company insiders own 0.49% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Kore Private Wealth LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $29,000. Bruderman Asset Management LLC grew its stake in shares of Teva Pharmaceutical Industries by 2,175.0% during the fourth quarter. Bruderman Asset Management LLC now owns 2,366 shares of the company’s stock worth $36,000 after buying an additional 2,262 shares during the last quarter. Coastal Investment Advisors Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $37,000. Lindbrook Capital LLC grew its stake in shares of Teva Pharmaceutical Industries by 61.2% during the first quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock worth $39,000 after buying an additional 945 shares during the last quarter. Finally, Cullen Frost Bankers Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $40,000. 65.12% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Teva Pharmaceutical Industries (TEVA) Shares Gap Down to $9.70” was published by Rockland Register and is the property of of Rockland Register. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://rocklandregister.com/2019/05/30/teva-pharmaceutical-industries-teva-shares-gap-down-to-9-70.html.

Teva Pharmaceutical Industries Company Profile (NYSE:TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: What economic reports are most valuable to investors?

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.